- Home
- EXAS vs CR Comparison
EXAS vs CR Comparison
Compare EXAS & CR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- CR
- Stock Information
- Founded
- EXAS 1995
- CR 1855
- Country
- EXAS United States
- CR United States
- Employees
- EXAS N/A
- CR N/A
- Industry
- EXAS Medical Specialities
- CR Metal Fabrications
- Sector
- EXAS Health Care
- CR Industrials
- Exchange
- EXAS Nasdaq
- CR Nasdaq
- Market Cap
- EXAS 8.8B
- CR 8.9B
- IPO Year
- EXAS N/A
- CR N/A
- Fundamental
- Price
- EXAS $43.06
- CR $152.14
- Analyst Decision
- EXAS Strong Buy
- CR Strong Buy
- Analyst Count
- EXAS 18
- CR 6
- Target Price
- EXAS $70.59
- CR $174.80
- AVG Volume (30 Days)
- EXAS 2.0M
- CR 382.5K
- Earning Date
- EXAS 05-07-2025
- CR 04-21-2025
- Dividend Yield
- EXAS N/A
- CR 0.61%
- EPS Growth
- EXAS N/A
- CR 13.55
- EPS
- EXAS N/A
- CR 5.05
- Revenue
- EXAS $2,758,867,000.00
- CR $2,131,200,000.00
- Revenue This Year
- EXAS $13.02
- CR $9.28
- Revenue Next Year
- EXAS $13.02
- CR $6.57
- P/E Ratio
- EXAS N/A
- CR $33.05
- Revenue Growth
- EXAS 10.37
- CR 14.45
- 52 Week Low
- EXAS $40.62
- CR $128.50
- 52 Week High
- EXAS $79.62
- CR $188.52
- Technical
- Relative Strength Index (RSI)
- EXAS 36.15
- CR 37.05
- Support Level
- EXAS $44.00
- CR $150.41
- Resistance Level
- EXAS $47.23
- CR $161.47
- Average True Range (ATR)
- EXAS 1.57
- CR 4.09
- MACD
- EXAS 0.06
- CR -0.05
- Stochastic Oscillator
- EXAS 15.86
- CR 0.03
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.